A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer

Published:2024-07 Issue: Volume: Page:
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Kothari Rushabh,Doshi Maulik^ORCID,Chaithanya P.K.,CT Satheesh,Kumar Anil,Mallavarapu Krishna Mohan,Nagarkar Rajnish,Mahobia Vijay,Bhatt Niraj,Priyadarshini K.L.,Gogia Ajay,Maksud Tanveer,Prasad Saurabh,Velavan K.,L․K․ Rajeev,SS Prakash,Talreja Vikas,Kalra Kaushal,Nemade Bhushan,Dastidar Aloke Ghosh,Gupta Tarachand,Patil Tushar,Bondarde Shailesh,Patel Pinakin,Gupta Sudeep,Biswas Ghanashyam,Vaghela Manan,Mahato Pinaki,Parekh Honey,Kalloli Mahesh,Shetty Rachan,Prakash Gaurav,Goel Anil,Mandal Srikrishna,Choudhury Tamohan,Jain Minish,Goswami Chanchal,H․M․ Yathish Kumar,Mukherjee K․K․,Shrivastava Rahul,Parmar Deven

Publisher

Elsevier BV

Reference13 articles.

1. Current and future burden of breast cancer: global statistics for 2020 and 2040;Arnold;Breast,2022

2. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer;Wang;BMC Cancer,2019

3. Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options;Francies;Am J Cancer Res,2020

4. Dissecting the biological heterogeneity of HER2-positive breast cancer;Schettini;Breast,2021

5. Breast cancer;Harbeck;Nat Rev Dis Pri,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28